<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176887</url>
  </required_header>
  <id_info>
    <org_study_id>TUjune2018</org_study_id>
    <nct_id>NCT04176887</nct_id>
  </id_info>
  <brief_title>Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus</brief_title>
  <official_title>Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted on 60 children suffering from status epilepticus who will be
      admitted to Pediatric Neurology Unit and Pediatric ICU of Tanta Hospital University.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this work is to compare the efficacy of Levetireacetam and Phenytoin in management
      of pediatric status epilepticus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cessation of convulsion</measure>
    <time_frame>30 minutes</time_frame>
    <description>seizure control based on stoppage of tonic and clonic movements and absence of epileptic activity in EEG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bradycardia</measure>
    <time_frame>6 hours</time_frame>
    <description>monitoring of heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory depression</measure>
    <time_frame>6 hours</time_frame>
    <description>monitoring of respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decreased conscious level</measure>
    <time_frame>6 hours</time_frame>
    <description>Glasgow Coma Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypotension</measure>
    <time_frame>6 hours</time_frame>
    <description>measurement of blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Comparison</condition>
  <condition>the Efficacy of Levetireacetam</condition>
  <condition>Phenytoin</condition>
  <condition>Management of Pediatric Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenytoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam Injection</intervention_name>
    <description>The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>levetiracetam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin Injection</intervention_name>
    <description>Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.</description>
    <arm_group_label>Phenytoin</arm_group_label>
    <other_name>Phenytoin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children suffering from convulsive generalized tonic clonic status epilepticus at any
             age.

        Exclusion Criteria:

          -  Non convulsive status epilepticus.

          -  Children with known contraindication or allergy to levetireacetam or phenytoin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amira Darwish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amira Darwish, MD</last_name>
    <phone>+1026380311</phone>
    <email>amira.darwish@med.tanta.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta University, Faculty of Medicine</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>3111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azza Kamal Al-shahawy, Professor of pediatrics</last_name>
      <email>azzaalshahawy@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Amira Hamed Darwish</investigator_full_name>
    <investigator_title>Professor of pediatrics and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Levetireacetam</keyword>
  <keyword>Phenytoin</keyword>
  <keyword>status epilepticus</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenytoin</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

